Kbc Group Nv Enanta Pharmaceuticals Inc Transaction History

Kbc Group Nv

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Feb 15, 2024	SELL	$11.09 - $22.13 $3,548 - $7,081	-320 Reduced 20.18%	1,266 $14,000
Q3 2022 Feb 15, 2024	BUY	$48.29 - $71.27 $76,587 - $113,034	1,586 New	1,586 $82,000
Q1 2022 Feb 14, 2024	BUY	$56.06 - $74.11 $88,911 - $117,538	1,586 New	1,586 $113,000
Q1 2022 May 06, 2022	BUY	$56.06 - $74.11 $88,911 - $117,538	1,586 New	1,586 $113,000
Q4 2019 Feb 11, 2020	SELL	$57.95 - $66.61 $744,251 - $855,472	-12,843 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$60.08 - $88.17 $546,968 - $802,699	-9,104 Reduced 41.48%	12,843 $771,000
Q2 2019 Jul 30, 2019	SELL	$81.3 - $97.35 $109,755 - $131,422	-1,350 Reduced 5.79%	21,947 $0
Q1 2019 May 10, 2019	SELL	$69.08 - $105.66 $1.25 Million - $1.91 Million	-18,124 Reduced 43.76%	23,297 $0
Q4 2018 Jan 31, 2019	BUY	$65.41 - $84.65 $1.32 Million - $1.71 Million	20,198 Added 95.17%	41,421 $2.93 Million
Q3 2018 Nov 14, 2018	BUY	$85.46 - $126.37 $1.81 Million - $2.68 Million	21,223 New	21,223 $0

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.